(Q50283110)

1 March 2018

title

Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection. (English)

1 reference

1 March 2018

0 references

1 reference

1 reference

Clinton B Mathias

3

0 references

author name string

Lucia Rose

1

1 reference

1 March 2018

Tiffany E Bias

2

1 reference

1 March 2018

Stacey B Trooskin

4

1 reference

1 March 2018

Jeffrey J Fong

5

1 reference

1 March 2018

language of work or name

English

0 references

publication date

8 May 2014

1 reference

1 March 2018

Annals of Pharmacotherapy

published in

1 reference

1 March 2018

volume

48

1 reference

1 March 2018

issue

8

1 reference

1 March 2018

page(s)

1019-1029

1 reference

1 March 2018

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Hepatitis C virus infection in USA: an estimate of true prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Evasion of intracellular host defence by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Regulation of hepatic innate immunity by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

The global health burden of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

The HCV NS5B nucleoside and non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Long noncoding RNAs associated with liver regeneration 1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/β-catenin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

The natural history of recurrent hepatitis C and what influences this

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014534194

21 January 2018

Identifiers

DOI

10.1177/1060028014534194

1 reference

1 March 2018

PubMed ID

24811396

1 reference

1 March 2018